Published in Nat Commun on March 13, 2015
High-risk human papillomavirus targets crossroads in immune signaling. Viruses (2015) 0.79
Diverse mechanisms evolved by DNA viruses to inhibit early host defenses. Crit Rev Biochem Mol Biol (2016) 0.78
Evasion of Host Immune Defenses by Human Papillomavirus. Virus Res (2016) 0.77
HPV disease transmission protection and control. Microb Cell (2016) 0.75
Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. Oncotarget (2016) 0.75
Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis. Front Immunol (2016) 0.75
High Levels of EBV-Encoded RNA 1 (EBER1) Trigger Interferon and Inflammation-Related Genes in Keratinocytes Expressing HPV16 E6/E7. PLoS One (2017) 0.75
Increased IFRD1 Expression in Human Colon Cancers Predicts Reduced Patient Survival. Dig Dis Sci (2017) 0.75
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 6.88
Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) (2006) 3.74
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol (2000) 2.44
Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol (1997) 2.21
Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene (2006) 2.20
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature (2009) 2.05
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology (2008) 1.62
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol (2003) 1.43
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol (2011) 1.37
Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene (2003) 1.36
Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol (2002) 1.32
Propagation, infection, and neutralization of authentic HPV16 virus. Virology (2004) 1.32
cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J Biol Chem (2000) 1.28
HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res (2010) 1.26
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26
Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One (2013) 1.26
Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene (2003) 1.24
ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol (2005) 1.23
Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res (2010) 1.23
Replication and assembly of human papillomaviruses. J Dent Res (2009) 1.20
High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol (2011) 1.16
Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog (2013) 1.15
The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem (2002) 1.11
High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins. Virology (2005) 1.10
Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol (2011) 1.08
Viral interference with innate immunity by preventing NF-κB activity. Cell Microbiol (2011) 1.03
Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol (2008) 1.02
The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med (2013) 1.01
E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-κ transcription in keratinocytes. PLoS One (2014) 0.99
Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J Virol (2011) 0.99
Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology (2012) 0.97
Role of TIS7 family of transcriptional regulators in differentiation and regeneration. Differentiation (2007) 0.95
PC4/Tis7/IFRD1 stimulates skeletal muscle regeneration and is involved in myoblast differentiation as a regulator of MyoD and NF-kappaB. J Biol Chem (2010) 0.94
Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem Pharmacol (2010) 0.92
Increased migration of Langerhans cells in response to HPV16 E6 and E7 oncogene silencing: role of CCL20. Cancer Immunol Immunother (2008) 0.92
Regulation of inducible nitric oxide synthase expression by viral A238L-mediated inhibition of p65/RelA acetylation and p300 transactivation. J Virol (2006) 0.92
Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer (2014) 0.90
Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J Gen Virol (2013) 0.86
Characterization of global transcription profile of normal and HPV-immortalized keratinocytes and their response to TNF treatment. BMC Med Genomics (2008) 0.86
Acetylation of conserved lysines in bovine papillomavirus E2 by p300. J Virol (2012) 0.85
CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV. J Invest Dermatol (2014) 0.83
Growth-regulating functions of human papillomavirus early gene products in cervical cancer cells acting dominant over enhanced epidermal growth factor receptor expression. Cancer Res (1990) 0.83
The N terminus of orf virus-encoded protein 002 inhibits acetylation of NF-κB p65 by preventing Ser(276) phosphorylation. PLoS One (2013) 0.83
EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production. Am J Physiol Lung Cell Mol Physiol (2014) 0.81